Skip to main content
Grant Details

Grant Number: 5R03CA096429-02 Interpret this number
Primary Investigator: Disario, James
Organization: University Of Utah
Project Title: Development of a Registry for Familial Pancreatic Cancer
Fiscal Year: 2003
Back to top


Abstract

DESCRIPTION (provided by applicant): Adenocarcinoma of the pancreas is the fourth most common cause of cancer death in the United States. It affects about 28,600 Americans each year and the mortality rate equals the incidence. Five to 10 percent of cases aggregate in families generally in a pattern consistent with autosomal dominant transmission with variable penetrance. There are a few rare syndromes for which a genetic etiology has been identified. However, the etiology has not been defined for the majority of familial cases. Identification of high-risk families and registration of the members is fundamental as a resource for gene discovery and future studies to refine identification of environmental factors, develop prevention strategies and test interventions. The aim of this proposal is to develop a high-risk population registry to provide a basis for future research and the specific objectives are: 1) Characterize the families with clustering of pancreatic cancer identified in the Utah Population Database (UPDB), 2) Create a registry of these families, 3) Procure blood and tissue blocks for DNA extraction, 4) Establish systems necessary so that the persons in this registry are available to participate in future studies to include gene discovery, identification and validation of environmental and lifestyle risk factors, chemoprevention trials, and interventional studies that potentially could include medical (targeted gene therapy, tumor vaccines), surgical and endoscopic modalities. The investigators intend to participate in an international consortium of registries currently in development to increase the statistical power for such studies as listed above. Established and validated genetic epidemiological techniques developed at this institution will be used to characterize the families. Probands, or next of kin for deceased persons, from informative families will be contacted and invited to participate using a validated method that assures confidentiality. For consenting families, a family advocate will be identified to recruit relatives and assist in refining the pedigree. Consent will be obtained to collect medical records and pancreatic cancer tissue blocks from the proband. The pedigrees will be expanded and registered. Subjects will be notified of future registry studies to include questionnaire completion, blood testing for DNA, and clinical trials to be developed. This proposal will allow the investigators to provide access a unique and important resource on a local and a national level. The goal corresponds with the National Cancer Institute Initiative to "identify, characterize, and understand the genes that cause or play a role in familial cancer."

Back to top


Publications

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials.
Authors: Kuptsova N. , Kopecky K.J. , Godwin J. , Anderson J. , Hoque A. , Willman C.L. , Slovak M.L. , Ambrosone C.B. .
Source: Blood, 2007-05-01; 109(9), p. 3936-44.
EPub date: 2006-12-29.
PMID: 17197435
Related Citations

A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study.
Authors: Sarosdy M.F. , Tangen C.M. , Weiss G.R. , Nestok B.R. , Benson M.C. , Schellhammer P.F. , Sagalowsky A.I. , Wood D.P. , Crawford E.D. .
Source: Urologic oncology, 2005 Nov-Dec; 23(6), p. 386-9.
PMID: 16301114
Related Citations

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.
Authors: Rothenberg M.L. , Liu P.Y. , Wilczynski S. , Nahhas W.A. , Winakur G.L. , Jiang C.S. , Moinpour C.M. , Lyons B. , Weiss G.R. , Essell J.H. , et al. .
Source: Gynecologic oncology, 2004 Dec; 95(3), p. 506-12.
PMID: 15581954
Related Citations

Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.
Authors: Stiff P.J. , Shpall E.J. , Liu P.Y. , Wilczynski S.P. , Callander N.S. , Scudder S.A. , Jazieh A.R. , Samlowski W. , McCoy J. , Alberts D.S. , et al. .
Source: Gynecologic oncology, 2004 Jul; 94(1), p. 98-106.
PMID: 15262126
Related Citations

Pancreatic carcinoma surveillance in patients with familial melanoma.
Authors: Parker J.F. , Florell S.R. , Alexander A. , DiSario J.A. , Shami P.J. , Leachman S.A. .
Source: Archives of dermatology, 2003 Aug; 139(8), p. 1019-25.
PMID: 12925390
Related Citations

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
Authors: Blayney D.W. , LeBlanc M.L. , Grogan T. , Gaynor E.R. , Chapman R.A. , Spiridonidis C.H. , Taylor S.A. , Bearman S.I. , Miller T.P. , Fisher R.I. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-07-01; 21(13), p. 2466-73.
PMID: 12829664
Related Citations

Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
Authors: Velasquez W.S. , Lew D. , Grogan T.M. , Spiridonidis C.H. , Balcerzak S.P. , Dakhil S.R. , Miller T.P. , Lanier K.S. , Chapman R.A. , Fisher R.I. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-05-15; 21(10), p. 1996-2003.
PMID: 12743154
Related Citations

Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Authors: Rothenberg M.L. , Liu P.Y. , Braly P.S. , Wilczynski S.P. , Hannigan E.V. , Wadler S. , Stuart G. , Jiang C. , Markman M. , Alberts D.S. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-04-01; 21(7), p. 1313-9.
PMID: 12663720
Related Citations

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
Authors: Anderson J.E. , Kopecky K.J. , Willman C.L. , Head D. , O'Donnell M.R. , Luthardt F.W. , Norwood T.H. , Chen I.M. , Balcerzak S.P. , Johnson D.B. , et al. .
Source: Blood, 2002-12-01; 100(12), p. 3869-76.
EPub date: 2002-08-01.
PMID: 12393614
Related Citations

Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
Authors: Leichman C.G. , Chansky K. , Macdonald J.S. , Doukas M.A. , Budd G.T. , Giguere J.K. , Abbruzzese J.L. , Southwest Oncology Group .
Source: Investigational new drugs, 2002 Nov; 20(4), p. 419-24.
PMID: 12448660
Related Citations

Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study.
Authors: Hawes D. , Liu P.Y. , Muggia F.M. , Wilczynski S. , Cote R. , Felix J. , Terada K. , Belt R.J. , Alberts D.S. .
Source: Gynecologic oncology, 2002 Oct; 87(1), p. 17-23.
PMID: 12468337
Related Citations

SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study.
Authors: Klein C.E. , Tangen C.M. , Braun T.J. , Hussain M.H. , Peereboom D.M. , Nichols C.R. , Rivkin S.E. , Dakhil S.R. , Crawford E.D. .
Source: The Prostate, 2002-09-01; 52(4), p. 264-8.
PMID: 12210486
Related Citations

Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study.
Authors: Whitehead R.P. , Lew D. , Flanigan R.C. , Weiss G.R. , Roy V. , Glode M.L. , Dakhil S.R. , Crawford E.D. .
Source: Journal of immunotherapy (Hagerstown, Md. : 1997), 2002 Jul-Aug; 25(4), p. 352-8.
PMID: 12142558
Related Citations

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
Authors: Berenson J.R. , Crowley J.J. , Grogan T.M. , Zangmeister J. , Briggs A.D. , Mills G.M. , Barlogie B. , Salmon S.E. .
Source: Blood, 2002-05-01; 99(9), p. 3163-8.
PMID: 11964279
Related Citations

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Authors: Sosman J.A. , Unger J.M. , Liu P.Y. , Flaherty L.E. , Park M.S. , Kempf R.A. , Thompson J.A. , Terasaki P.I. , Sondak V.K. , Southwest Oncology Group .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-04-15; 20(8), p. 2067-75.
PMID: 11956267
Related Citations

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.
Authors: Sondak V.K. , Liu P.Y. , Tuthill R.J. , Kempf R.A. , Unger J.M. , Sosman J.A. , Thompson J.A. , Weiss G.R. , Redman B.G. , Jakowatz J.G. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-04-15; 20(8), p. 2058-66.
PMID: 11956266
Related Citations

Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment.
Authors: Hundahl S.A. , Macdonald J.S. , Benedetti J. , Fitzsimmons T. , Southwest Oncology Group and the Gastric Intergroup .
Source: Annals of surgical oncology, 2002 Apr; 9(3), p. 278-86.
PMID: 11923135
Related Citations

Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial.
Authors: Moinpour C.M. , Lyons B. , Grevstad P.K. , Lovato L.C. , Crowley J. , Czaplicki K. , Buckner Z.M. , Ganz P.A. , Kelly K. , Gandara D.R. .
Source: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2002 Mar; 11(2), p. 115-26.
PMID: 12018735
Related Citations

Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Authors: Ramsey S.D. , Moinpour C.M. , Lovato L.C. , Crowley J.J. , Grevstad P. , Presant C.A. , Rivkin S.E. , Kelly K. , Gandara D.R. .
Source: Journal of the National Cancer Institute, 2002-02-20; 94(4), p. 291-7.
PMID: 11854391
Related Citations

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
Authors: List A.F. , Kopecky K.J. , Willman C.L. , Head D.R. , Persons D.L. , Slovak M.L. , Dorr R. , Karanes C. , Hynes H.E. , Doroshow J.H. , et al. .
Source: Blood, 2001-12-01; 98(12), p. 3212-20.
PMID: 11719356
Related Citations

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.
Authors: Press O.W. , LeBlanc M. , Lichter A.S. , Grogan T.M. , Unger J.M. , Wasserman T.H. , Gaynor E.R. , Peterson B.A. , Miller T.P. , Fisher R.I. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-11-15; 19(22), p. 4238-44.
PMID: 11709567
Related Citations

Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
Authors: Rothenberg M.L. , Liu P.Y. , Wilczynski S. , Hannigan E.V. , Weiner S.A. , Weiss G.R. , Hunter V.J. , Chapman J.A. , Tiersten A. , Kohler P.C. , et al. .
Source: Gynecologic oncology, 2001 Aug; 82(2), p. 317-22.
PMID: 11531286
Related Citations

Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
Authors: Kelly K. , Lovato L. , Bunn P.A. , Livingston R.B. , Zangmeister J. , Taylor S.A. , Roychowdhury D. , Crowley J.J. , Gandara D.R. , Southwest Oncology Group .
Source: Clinical cancer research : an official journal of the American Association for Cancer Research, 2001 Aug; 7(8), p. 2325-9.
PMID: 11489808
Related Citations

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
Authors: Kelly K. , Crowley J. , Bunn P.A. , Presant C.A. , Grevstad P.K. , Moinpour C.M. , Ramsey S.D. , Wozniak A.J. , Weiss G.R. , Moore D.F. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-07-01; 19(13), p. 3210-8.
PMID: 11432888
Related Citations

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).
Authors: Pienta K.J. , Fisher E.I. , Eisenberger M.A. , Mills G.M. , Goodwin J.W. , Jones J.A. , Dakhil S.R. , Crawford E.D. , Hussain M.H. .
Source: The Prostate, 2001-03-01; 46(4), p. 257-61.
PMID: 11241547
Related Citations

Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study.
Authors: Samlowski W.E. , Gundacker H. , Kuebler J.P. , Giguere J.K. , Mills G.M. , Schuller D.E. , Ensley J.F. .
Source: Investigational new drugs, 2001; 19(4), p. 311-5.
PMID: 11561690
Related Citations




Back to Top